Source comparison
Sermorelin Work for Pulsatile GH Studies: Evidence vs Recombinant GH
Mechanism Stimulates endogenous pituitary GH release via GHRH receptors Direct GH replacement. Bypasses hypothalamic-pituitary axis entirely Sermorelin preserves physiological feedback; rhGH suppresses endogenous production Secretory Pattern Discrete pulsatile
This comparison does not assign a generated winner or score.
- Mechanism
- Stimulates endogenous pituitary GH release via GHRH receptors
- Direct GH replacement. Bypasses hypothalamic-pituitary axis entirely
- Sermorelin preserves physiological feedback; rhGH suppresses endogenous production
- Secretory Pattern
- Discrete pulsatile bursts (30–60 min peak, return to baseline by 3 hours)
- Sustained supraphysiological elevation lasting 8–12 hours per dose
- Only sermorelin replicates natural pulsatile kinetics
- IGF-1 Elevation
- Modest increase (10–30% above baseline). Subject to negative feedback
- Dose-dependent; can exceed physiological range by 2–3× with standard dosing
- Sermorelin cannot override somatostatin; rhGH can
- Regulatory Feedback
- Fully intact. Somatostatin and IGF-1 limit response amplitude
- Bypassed. Exogenous GH suppresses endogenous pulsatile secretion for 24–48 hours
- Sermorelin models aging; rhGH models deficiency replacement
- Use in Pulsatile Studies
- Ideal for modeling hypothalamic aging, pulse frequency decline, amplitude loss
- Not suitable. Eliminates endogenous pulsatility entirely during treatment
- Sermorelin is the only validated tool for pulsatile GH research
- Plasma Half-Life
- 10–20 minutes (peptide cleared rapidly; GH pulse lasts 2–3 hours)
- 3–4 hours for subcutaneous rhGH (longer-acting pegylated forms exist)
- Sermorelin's short half-life allows repeat dosing within the same day for multi-pulse studies